News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LFB S.A. Announces That First Patient Has Begun Treatment With New Coagulation Factor VIIa (Recombinant) In Global Phase 3 Clinical Trial In Hemophilia A And B With Inhibitors


5/14/2014 10:16:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
LFB S.A.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES